Antivirals - An increasingly healthy investment

Nature Biotechnology

Volumn 25, Issue 12, 2007, Pages 1390-1393

  McCarthy, Brian ^a,b  

^a Merriman Curhan Ford and Co   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; AMPLIGEN; ANA 975; ANTIVIRUS AGENT; BAVITUXIMAB; CELLULOSE SULFATE; CIVACIR; CPG 10101; DIDANOSINE; EMTRICITABINE; GLYMINOX; IMO 2125; LAMIVUDINE PLUS ZIDOVUDINE; R 7128; RIBAVIRIN; SAQUINAVIR; SCAVVY; STAVUDINE; UNCLASSIFIED DRUG; VIVAGEL; VX 950; XTL 6865; ZALCITABINE;

BIOTECHNOLOGY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MARKETING; DRUG TOLERABILITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOMODULATION; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; TOXICOLOGY; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; INVESTMENTS; UNITED STATES; VIRUS DISEASES;

EID: 36849049776     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1207-1390     Document Type: Note

References (2)

1. Anonymous. The World Market for Anti-Infectives, Volume III. Antiviral Drugs (Kalorama Information, Rockville, MD, USA, 2007).
2. Anonymous. The Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape (Arrowhead Publishers, Minneapolis, MN, USA, 2007).